IGF1R and neoplasm: In human tumor cells co-expressing IGF-1R and IR, it was reported that co-targeting IGF-1R and IR with OSI-906 provides superior anti-tumor efficacy compared with targeting IGF-1R alone using a neutralizing antibody (Buck et al., 2010).